We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' Cosentyx Superior to Stelara in Psoriasis Study
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for psoriasis drug Cosentyx. The label update includes 52-week data from the CLEAR study which demonstrated the long-term superiority of Cosentyx over Johnson & Johnson’s (JNJ - Free Report) Stelara (ustekinumab) in psoriasis.
The study revealed that Cosentyx was superior to Stelara in achieving and sustaining a PASI 90 response (76% versus 61%) and was significantly better in achieving a PASI 100 (clear skin) response (46% versus 36%) at week 52.
Psoriasis drug, Cosentyx, was also approved for the treatment of two new indications – ankylosing spondylitis (AS) and psoriatic arthritis (PsA) – in the EU in 2016. Moreover, the FDA approved Cosentyx for AS and PsA in Jan 2016. The uptake of
Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie’s (ABBV - Free Report) Humira and Amgen’s (AMGN - Free Report) Enbrel. Cosentyx achieved the blockbuster status in 2016 recording over $1 billion of sales.
Approximately 60 million patients globally are impacted by psoriasis. The addition of the study data in the product label reflects the benefit of Cosentyx for patients living with this chronic condition.
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx (in all three indications psoriasis, psoriatic arthritis and ankylosing spondylitis) Entresto, and Kisqali and a deep pipeline with candidates like CTL019, BAF312, AMG 334, RTH258.
Novartis has outperformed the Zacks classified industry in the last six months. The stock has rallied 13.0% compared with the Large Cap Pharmaceuticals industry’s 11.1% gain.
Going forward, we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis. Also, strong performance of growth products should be able to offset the impact of generic competition for Gleevec.
Zacks Rank
Novartis currently carries a Zacks Rank #4 (Sell).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Novartis' Cosentyx Superior to Stelara in Psoriasis Study
Novartis AG (NVS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for psoriasis drug Cosentyx. The label update includes 52-week data from the CLEAR study which demonstrated the long-term superiority of Cosentyx over Johnson & Johnson’s (JNJ - Free Report) Stelara (ustekinumab) in psoriasis.
The study revealed that Cosentyx was superior to Stelara in achieving and sustaining a PASI 90 response (76% versus 61%) and was significantly better in achieving a PASI 100 (clear skin) response (46% versus 36%) at week 52.
Psoriasis drug, Cosentyx, was also approved for the treatment of two new indications – ankylosing spondylitis (AS) and psoriatic arthritis (PsA) – in the EU in 2016. Moreover, the FDA approved Cosentyx for AS and PsA in Jan 2016. The uptake of
Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie’s (ABBV - Free Report) Humira and Amgen’s (AMGN - Free Report) Enbrel. Cosentyx achieved the blockbuster status in 2016 recording over $1 billion of sales.
Approximately 60 million patients globally are impacted by psoriasis. The addition of the study data in the product label reflects the benefit of Cosentyx for patients living with this chronic condition.
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx (in all three indications psoriasis, psoriatic arthritis and ankylosing spondylitis) Entresto, and Kisqali and a deep pipeline with candidates like CTL019, BAF312, AMG 334, RTH258.
Novartis has outperformed the Zacks classified industry in the last six months. The stock has rallied 13.0% compared with the Large Cap Pharmaceuticals industry’s 11.1% gain.
Going forward, we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis. Also, strong performance of growth products should be able to offset the impact of generic competition for Gleevec.
Zacks Rank
Novartis currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.See This Ticker Free >>